CN106579421A - Composition containing curcumin and beta-glucan and application thereof - Google Patents
Composition containing curcumin and beta-glucan and application thereof Download PDFInfo
- Publication number
- CN106579421A CN106579421A CN201611056141.0A CN201611056141A CN106579421A CN 106579421 A CN106579421 A CN 106579421A CN 201611056141 A CN201611056141 A CN 201611056141A CN 106579421 A CN106579421 A CN 106579421A
- Authority
- CN
- China
- Prior art keywords
- beta glucan
- beta
- food
- composition containing
- curcumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 92
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 59
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 59
- 239000004148 curcumin Substances 0.000 title claims abstract description 44
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 44
- 229940109262 curcumin Drugs 0.000 title claims abstract description 44
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 8
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 244000163122 Curcuma domestica Species 0.000 claims description 17
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 14
- 235000003373 curcuma longa Nutrition 0.000 claims description 14
- 235000013976 turmeric Nutrition 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 229920001491 Lentinan Polymers 0.000 claims description 12
- 229940115286 lentinan Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229920001503 Glucan Polymers 0.000 claims description 5
- 244000197580 Poria cocos Species 0.000 claims description 5
- 235000008599 Poria cocos Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 235000014375 Curcuma Nutrition 0.000 claims description 2
- 240000009138 Curcuma zedoaria Species 0.000 claims description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 2
- 240000001080 Grifola frondosa Species 0.000 claims description 2
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 235000019509 white turmeric Nutrition 0.000 claims description 2
- 239000007887 hard shell capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
- 229930182478 glucoside Natural products 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010082786 Interleukin-1alpha Proteins 0.000 description 4
- 102000004125 Interleukin-1alpha Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 229920000392 Zymosan Polymers 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000222481 Schizophyllum commune Species 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- -1 10kg) Polymers 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition containing curcumin and beta-glucan and application thereof. In the composition, a mass ratio of curcumin and beta-glucan is 1:1-1:3, and have synergistic effect within the ratio range and have better effect than either cucumin or beta-glucan. The composition is applied in preparation of anti-inflammation healthcare food, functional food and food for special medical use, and the anti-inflammation healthcare food, functional food and food for special medical use prepared with the composition have good prevention and healthcare effects on people having chronic inflammation risk like obesity, hyperlipidemia, diabetes, tumor disease or blood vessel atherosis.
Description
Technical field
The invention belongs to field of food health care, and in particular to a kind of composition containing curcumin and beta glucan and its should
With.
Background technology
Inflammation is that body immune system antagonism originates in raw response.It is a series of chain that long-term chronic inflammation can be produced
Reaction, and ultimately result in the quick of the such as atherosis chronic disease of tumour, rheumatoid arthritis, diabetes, arteries
Development (Yan Fengchen presses the progress [J] of western Zhao Changhai chronic inflammations and relationship between atherosclerosis. and modern biomedical is entered
Exhibition .2011.20:3964-3967.) (the just big fat progress [J] with chronic inflammation of Zhan Lili Yang Zhi autumns Fu. Chinese cell
Biological journal .2011.33 (3):297-305.) (grandson Hou Jiajie is again into STAT3：Chronic inflammation mediate tumor occur and be in progress
Key node [J]. Progress in Biochemistry and Biophysics .2014,41 (1):69-78.).In view of inflammation is in most of chronic diseases
Effect played in disease, needs anti-inflammatory drug to prevent and auxiliary treatment inflammation.Although including Sai meter Kao former times, aspirin, cloth
The different steroid such as ibuprofen, phenylbutazone and NSAIDs can be used to treat diseases associated with inflammation, but their great majority all have
Have side effect (king's chess text, Song Derong, Li Jianyong, etc. anti-inflammatory drug and mechanism of action latest Progress [J]. Chinese herding beast
Doctor, 2010,37 (3):211-214.).Therefore, natural origin, safe anti-inflammatory substance are excavated and seems very necessary.
Curcumin (curcumin) is earliest that a kind of low molecule separated from turmeric Curcuma longa L. is more
Phenolic compounds.Curcumin is one of maximum natural food colour of current global sales, by the World Health Organization and U.S.'s food
The tight security material of drug administration's accreditation, the food additives for being permitted to use by many countries.With modern medicine
To the increasingly deep of curcumin research, reported that curcumin is particularly splendid in terms of anti-oxidant and antiinflammatory action, curcumin it is many
Kind of pharmacologically active is all anti-oxidant to its, anti-inflammatory activity related (Di Jianbin, Gu Zhenlun, Zhao Xiaodong, Qian Peigang, Jiang little Gang, Guo Ciyi
The anti-oxidant and Research progress in anti-inflammatory effects [J] of curcumin. Chinese herbal medicine .2010.41 (5):Attached 18-21.).Research discovery, turmeric
Activity of the element in terms of anti-inflammatory has suitable level with the steroid drugs such as Indomethacin and phenylbutazone and non-steroidal drug, and
Safe (Aqqarwal B.B, Harikumar KB.Potential therapeutic effect of curucmin,
the anti-infl-ammatory agent,against neurodegenerative,cardiovascular,
pulmonary,metabolic,autoimmune and neoplastic diseases[J].Int J Biochem Cell
Biol,2009,41(1):40-59.)。
Beta glucan is a class with β -1, the polymer formed based on the bonded glucose of 3 glucosides, is connected with or without β -1,6
The side chain for connecing.In natural material, content is higher in mushroom, Poria cocos, rainbow conk, yeast, grifola frondosus, schizophyllum commune, oat, barley etc..
Beta glucan source is different, and structure there is also difference.The beta glucan extracted in fungi, such as lentinan, Schizophyllum commune Fr polysaccharides, its
Structure is by the bonded branch of the bonded main chain of β -1,3 glucosides and β -1,6 glucosides；Zymosan is also by β -1,3- glucosides
Bonded main chain and β -1, the beta glucan of 6- glycosidic bonds branch；The beta glucan extracted in cereal, such as oat polysaccharide and big
Wheat glucan, in their chain structures not only have β -1,3 and β 1,6- glycosidic bonds, centre also accompany β-Isosorbide-5-Nitrae glucosides it is bonded point
(draw morning cutting edge of a knife or a sword Guo and keep eastern application for organizing the Olympic Games. beta glucan progress [J]. Harbin University of Commerce's journal (natural science edition), 2013,
29(5):516-520.).Modern study shows that the physiologically active of beta glucan includes immunological regulation, antitumor, hypoglycemic, drop
The aspects such as blood fat, antithrombotic, radioresistance (Wang Xiaoling, Yang Hailong, Liu Gaoqiang, etc. the structure of edible and medical fungi beta glucan, structure effect
Relation and its pharmacological action [J]. edible mushroom journal, 2014 (1):35-41.).
The content of the invention
It is an object of the invention to provide a kind of curcumin with synergistic function and beta glucan in terms of anti-inflammatory
Composition, for preparing the health food with anti-inflammatory properties, functional food and special medicine purposes food.
For achieving the above object, the present invention is employed the following technical solutions.
A kind of composition containing curcumin and beta glucan, in composition, curcumin is with the mass ratio of beta glucan
1:1-1:3。
Preferably, the beta glucan is β-lentinan, Poria cocos beta glucan, carboxymethyl Poria cocos beta glucan, cloud
One or more kinds of combinations in sesame beta glucan, grifola frondosa beta-glucose and yeast beta-dextran.
It is furthermore preferred that the beta glucan be β-lentinan, rainbow conk beta glucan, yeast beta-dextran and oat β-
One or more kinds of combinations in glucan.
Most preferably, the beta glucan is in β-lentinan, yeast beta-dextran and avenabeta glucosan
Plant or two or more combinations.
Preferably, the curcumin is from one or more of turmeric, root tuber of aromatic turmeric and curcuma zedoary.
It is furthermore preferred that the curcumin is from turmeric.
A kind of described composition containing curcumin and beta glucan is preparing health food, work(with anti-inflammatory properties
Application that can be in food and special medicine purposes food, the health food with anti-inflammatory properties of preparation, functional food and special
Medical science formula purposes food is used for auxiliary treatment and the prevention of the disease related to chronic inflammation.
Preferably, the formulation of the health food, functional food and special medicine purposes food is soft capsule, ebonite
Capsule, tablet, pulvis or granule, oral liquid, beverage, jelly or candy.
Compared with prior art, the invention has the advantages that and beneficial effect：
(1) 1 is compared in composition quality:1-1:In the range of 3, curcumin and beta glucan have synergistic function, than list
One curcumin or beta glucan effect are good；
(2) eaten using the health care made by the composition containing curcumin and beta glucan of the invention with anti-inflammatory properties
Product, functional food and special medicine purposes food, to athero- hard including obesity, high fat of blood, diabetes, neoplastic disease or artery
The chronic inflammation risk population of change has good functions of prevention and health care.
Specific embodiment
With reference to embodiments being explained further the present invention, but the present invention do not limited in any form, do not made
In the case of explanation, raw material according to the present invention is the convenient source and method of this area with method.
Embodiment 1
A kind of composition containing curcumin Yu beta glucan, is prepared from by the component of following weight proportioning：Turmeric carries
Take thing (in terms of curcumin, 10kg), lentinan (in terms of beta glucan, 10kg).
Embodiment 2
A kind of composition containing curcumin Yu beta glucan, is prepared from by the component of following weight proportioning：Turmeric carries
Take thing (in terms of curcumin, 10kg), lentinan (in terms of beta glucan, 10kg), coriolan (in terms of beta glucan) 20kg.
Embodiment 3
A kind of composition containing curcumin Yu beta glucan, is prepared from by the component of following weight proportioning：Turmeric carries
Take thing (in terms of curcumin, 10kg), zymosan (in terms of beta glucan, 30kg).
Embodiment 4
A kind of composition containing curcumin Yu beta glucan, is prepared from by the component of following weight proportioning：Turmeric carries
Take thing (in terms of curcumin, 10kg), zymosan (in terms of beta glucan, 10kg), coriolan (in terms of beta glucan,
10kg)。
Embodiment 5
A kind of composition containing curcumin Yu beta glucan, is prepared from by the component of following weight proportioning：Turmeric carries
Take thing (in terms of curcumin, 10kg), lentinan (in terms of beta glucan, 10kg), zymosan (in terms of beta glucan,
10kg), oat polysaccharide (in terms of beta glucan, 10kg).
Embodiment 6
Compliance test result is tested：Antiinflammatory action of the embodiment to inflammatory model mouse
The composition containing curcumin and beta glucan that embodiment 1,2,3,4 and 5 is prepared uses respectively 1wt%CMC (hydroxyls
Sodium carboxymethylcellulose pyce) aqueous dissolution, it is configured to stablize CMC suspension；In addition, individually preparing ginger with the 1wt%CMC aqueous solution again
Flavine CMC solution, β-lentinan CMC solution and 1wt%CMC solution are negative control；Curcumin+β-the Portugal of each test group
Glycan, curcumin or beta glucan given low are 80mg/kgd.1 group of embodiment, 2 groups of embodiment, embodiment 3 are designated as respectively
Group, 4 groups of embodiment, 5 groups of embodiment, β-lentinan group, curcumin group, normal group and model control group.Mouse is administered body
Product is based on 0.2ml/10g.Every group of quantity n=10 of mouse, male and female half and half.SPF levels C57BL/ system mouse, September age, body weight 22～
50g。
Experimental technique
Normal group intraperitoneal injection of saline, the μ g/ of remaining each group intraperitoneal injection of LPS LPS 20 only, once in a week, connect
It is continuous 4 weeks；Jing after lps injection, inflammatory cytokine TNF-α, IFN-γ, IL-1 α are more notable than normal group in remaining each group serum
Raise (p<0.001) inflammatory model modeling success, is shown.
After modeling success, normal group and the daily gavage of model control group mouse give the 1wt%CMC aqueous solution, remaining each group
The daily gavage counter sample liquid of animal once, is tested the 30th day, and each group mouse takes blood, separates serum, is taken off cervical vertebra and is put to death mouse.Press
According to the explanation of kit, TNF-α, IFN-γ, the content of IL-1 α in detection serum.
Data processing
Using SPSS softwares, counted with the comparative approach two-by-two of mean x between multiple experimental groups and a control group, P<
0.05 is that difference is statistically significant.
As a result
As shown in table 1, oral administration gavage sample liquid compares experimental result after 30 days with model control group, curcumin group, mushroom
Beta glucan plays the role of to reduce TNF-α and IL-1 α (p<0.05), the secretion to the IFN-γ factor does not make significant difference.From enforcement
Can see in the result of example 1-5, after curcumin and beta glucan are compounded, each embodiment sample group can pole significantly reduce inflammatory
Level (the p of factor TNF-α, IFN-γ, IL-1 α in serum<0.05-0.01), thus prove that curcumin exists with beta glucan
Anti-inflammatory aspect has synergistic function.
The impact that the test specimen of table 1 is secreted to mice serum inflammatory cytokine(pg/ml)
Note：Compare with normal group, * P<0.05, * * P<0.01,***P<0.001；Compare with model control group,△P<0.05
,△ΔP<0.01；
The above, the only present invention preferably specific embodiment, but protection scope of the present invention is not limited thereto, and appoints
What those familiar with the art the invention discloses technical scope in, technology according to the present invention scheme and its structure
Think in addition equivalent or change, all should cover within the scope of the present invention.
Claims (8)
1. a kind of composition containing curcumin and beta glucan, it is characterised in that in composition, curcumin and beta glucan
Mass ratio is 1:1-1:3.
2. a kind of composition containing curcumin and beta glucan according to claim 1, it is characterised in that the β-Portugal
Glycan be β-lentinan, Poria cocos beta glucan, carboxymethyl Poria cocos beta glucan, rainbow conk beta glucan, Grifola frondosa beta-Portugal gather
One or more kinds of combinations in sugar and yeast beta-dextran.
3. a kind of composition containing curcumin and beta glucan according to claim 1, it is characterised in that the β-Portugal
Glycan be β-lentinan, rainbow conk beta glucan, yeast beta-dextran and avenabeta glucosan in one or two kinds of with
On combination.
4. a kind of composition containing curcumin and beta glucan according to claim 1, it is characterised in that the β Portugals
Glycan is the one or more kinds of combinations in β-lentinan, yeast beta-dextran and avenabeta glucosan.
5. a kind of composition containing curcumin and beta glucan according to claim 1, it is characterised in that the turmeric
Usually from one or more of turmeric, root tuber of aromatic turmeric and curcuma zedoary.
6. a kind of composition containing curcumin and beta glucan according to claim 1, it is characterised in that the turmeric
Usually from turmeric.
7. a kind of composition containing curcumin and beta glucan described in any one of claim 1-6 is being prepared with anti-inflammatory work(
Can health food, functional food and special medicine purposes formula food in application, it is characterised in that preparation with anti-inflammatory
The health food of function, functional food and special medicine purposes food be used for the auxiliary treatment of the disease related to chronic inflammation and
Prevention.
8. application according to claim 7, it is characterised in that the health food, functional food and special medicine purposes
The formulation of formula food is soft capsule, hard shell capsules, tablet, pulvis or granule, oral liquid, beverage, jelly or candy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611056141.0A CN106579421A (en) | 2016-11-24 | 2016-11-24 | Composition containing curcumin and beta-glucan and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611056141.0A CN106579421A (en) | 2016-11-24 | 2016-11-24 | Composition containing curcumin and beta-glucan and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106579421A true CN106579421A (en) | 2017-04-26 |
Family
ID=58593367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611056141.0A Pending CN106579421A (en) | 2016-11-24 | 2016-11-24 | Composition containing curcumin and beta-glucan and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106579421A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310321A (en) * | 2018-04-25 | 2018-07-24 | 李军 | Composition including its drug with blood fat reducing function and preparation method thereof |
| WO2021173020A1 (en) * | 2020-02-24 | 2021-09-02 | Nomi Biotech Corporation Sp. Z O.O. | Formulation of a turmeric extract comprising curcuminoids, method of production thereof, the use of the formulation and products comprising thereof |
| CN114796259A (en) * | 2022-02-17 | 2022-07-29 | 泉州雷恩生化有限公司 | Medicine for inhibiting pulmonary nodule and inflammation and its preparing method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| CN106075399A (en) * | 2016-07-22 | 2016-11-09 | 简婷婷 | For the compositions of corticosteroid dermatitis, preparation and preparation method and application |
| CN106243239A (en) * | 2016-07-29 | 2016-12-21 | 山东大学齐鲁医院 | A kind of solubility for improving hepatitis immunity little molecule β 1,3 glucosan |
-
2016
- 2016-11-24 CN CN201611056141.0A patent/CN106579421A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| CN106075399A (en) * | 2016-07-22 | 2016-11-09 | 简婷婷 | For the compositions of corticosteroid dermatitis, preparation and preparation method and application |
| CN106243239A (en) * | 2016-07-29 | 2016-12-21 | 山东大学齐鲁医院 | A kind of solubility for improving hepatitis immunity little molecule β 1,3 glucosan |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108310321A (en) * | 2018-04-25 | 2018-07-24 | 李军 | Composition including its drug with blood fat reducing function and preparation method thereof |
| WO2021173020A1 (en) * | 2020-02-24 | 2021-09-02 | Nomi Biotech Corporation Sp. Z O.O. | Formulation of a turmeric extract comprising curcuminoids, method of production thereof, the use of the formulation and products comprising thereof |
| CN114796259A (en) * | 2022-02-17 | 2022-07-29 | 泉州雷恩生化有限公司 | Medicine for inhibiting pulmonary nodule and inflammation and its preparing method |
| CN114796259B (en) * | 2022-02-17 | 2024-06-07 | 泉州雷恩生化有限公司 | Medicine for inhibiting pulmonary nodule and inflammation and its prepn |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niu et al. | Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review | |
| Franco et al. | Psyllium (Plantago ovata Forsk): From evidence of health benefits to its food application | |
| Ganesan et al. | Anti-diabetic effects and mechanisms of dietary polysaccharides | |
| Wei et al. | Structure characterization and immunomodulating effects of polysaccharides isolated from Dendrobium officinale | |
| Ríos | Chemical constituents and pharmacological properties of Poria cocos | |
| Singh et al. | Avena sativa (Oat), a potential neutraceutical and therapeutic agent: an overview | |
| Giuntini et al. | The effects of soluble dietary fibers on glycemic response: an overview and futures perspectives | |
| Jeong et al. | Macrophage immunomodulating and antitumor activities of polysaccharides isolated from Agaricus bisporus white button mushrooms | |
| Mayell | Maitake extracts and their therapeutic potential-a review | |
| Kimura | Natural products and biological activity of the pharmacologically active cauliflower mushroom Sparassis crispa | |
| Lu et al. | Recent developments in Inonotus obliquus (Chaga mushroom) polysaccharides: Isolation, structural characteristics, biological activities and application | |
| Thakur et al. | Rasayana properties of Ayurvedic herbs: Are polysaccharides a major contributor | |
| Jiang et al. | Protein-bound anthocyanin compounds of purple sweet potato ameliorate hyperglycemia by regulating hepatic glucose metabolism in high-fat diet/streptozotocin-induced diabetic mice | |
| Ashour et al. | A review on the main phytoconstituents, traditional uses, inventions, and patent literature of gum Arabic emphasizing Acacia seyal | |
| CN102215850B (en) | Composition containing fucoxanthin extract | |
| De Araújo et al. | Effects of beta‐glucans ingestion (Saccharomyces cerevisiae) on metabolism of rats receiving high‐fat diet | |
| KR101349136B1 (en) | Composition for preventing or treating fatty liver or hyperlipidemia comprising insent glycosaminoglycan | |
| Zhang et al. | A polysaccharide from Ganoderma atrum inhibits tumor growth by induction of apoptosis and activation of immune response in CT26-bearing mice | |
| CN106579421A (en) | Composition containing curcumin and beta-glucan and application thereof | |
| CN106901367A (en) | The composition and preparation method and purposes of a kind of balance blood sugar | |
| Lin et al. | Research on a specialty mushroom (Pleurotus tuber-regium) as a functional food: chemical composition and biological activities | |
| Wang et al. | Lycium genus polysaccharide: an overview of its extraction, structures, pharmacological activities and biological applications | |
| Hu et al. | Extraction, purification, structural characteristics, biological activities, and applications of the polysaccharides from Zingiber officinale Roscoe.(Ginger): A review | |
| WO2020221184A1 (en) | Pharmaceutical composition with effect of reducing uric acid | |
| Wang et al. | Extraction, purification, structural characteristics, biological activity and application of polysaccharides from Portulaca oleracea L.(Purslane): a review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |
|
| RJ01 | Rejection of invention patent application after publication |